ADIPOKINE AND CYTOKINE PROFILES IN METABOLIC SYNDROME: EFFECTS OF LEPTIN, ADIPONECTIN, AND GHRELIN ON ENZYMES OF LIPID AND CARBOHYDRATE METABOLISM
Keywords:
metabolic syndrome, leptin, adiponectin, ghrelin, pro-inflammatory cytokines, AMPK, acetyl-CoA carboxylase, PEPCK, lipid and carbohydrate metabolism.Abstract
Metabolic syndrome represents a cluster of interrelated cardiometabolic disturbances driven by visceral adiposity, chronic low-grade inflammation, and systemic insulin resistance. Central to this pathophysiology is a disrupted endocrine crosstalk between adipose-derived adipokines, pro-inflammatory cytokines, and gastrointestinal peptide hormones that directly modulate key rate-limiting enzymes of lipid and carbohydrate metabolism. This structured IMRAD literature review, prepared at the Department of Biological Chemistry of Andijan State Medical Institute, synthesizes contemporary biochemical and molecular evidence regarding the adipokine-cytokine profile in metabolic syndrome, focusing specifically on how leptin, adiponectin, and ghrelin regulate enzymatic pathways. Under physiological conditions, leptin and adiponectin activate AMP-activated protein kinase (AMPK) in skeletal muscle and liver, phosphorylating and inhibiting acetyl-CoA carboxylase (ACC) to relieve malonyl-CoA inhibition of carnitine palmitoyltransferase-1 (CPT-1) and stimulate mitochondrial fatty acid beta-oxidation. Simultaneously, adiponectin suppresses hepatic gluconeogenic enzymes—phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase)—and activates receptor-associated ceramidase. In metabolic syndrome, however, visceral fat expansion elevates tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β), inducing suppressor of cytokine signaling-3 (SOCS-3) and c-Jun N-terminal kinase (JNK1) pathways that trigger leptin resistance, hypoadiponectinemia, and suppressed acylated ghrelin signaling. Understanding these enzymatic and endocrine shifts provides critical diagnostic biomarkers and targeted biochemical strategies for managing metabolic syndrome.
References
1.Lehr, S., Hartwig, S., & Sell, H. / MDPI Biomedicines Review. (2025). Adipose tissue insulin resistance: A key driver of metabolic syndrome. Biomedicines, 13(10), 2376. https://www.mdpi.com/2227-9059/13/10/2376
2.Tissue-Specific Effects of Leptin on Glucose and Lipid Metabolism. (2021). Tissue-specific effects of leptin on glucose and lipid metabolism. Endocrine Reviews / PMC7846142. https://pmc.ncbi.nlm.nih.gov/articles/PMC7846142/
3.The Role of Adipokines in Health and Disease. (2023). The role of adipokines in health and disease. Biomedicines, 11(5), 1290. https://pmc.ncbi.nlm.nih.gov/articles/PMC10216288/
4.Adiponectin and Leptin Adipocytokines in Metabolic Syndrome. (2020). Adiponectin and leptin adipocytokines in metabolic syndrome: What is its importance? Colombia Médica / D-NB. https://d-nb.info/1224579291/34
5.Adipokines Mediate Inflammation and Insulin Resistance. (2013). Adipokines mediate inflammation and insulin resistance. Frontiers in Endocrinology / PMC3679475. https://pmc.ncbi.nlm.nih.gov/articles/PMC3679475/
6.Adipokines and Insulin Resistance. (2008). Adipokines and insulin resistance: Molecular signaling mechanisms. Endocrine Reviews / PMC2582855. https://pmc.ncbi.nlm.nih.gov/articles/PMC2582855/
7.Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis. (2016). Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Diabetes / PMC4864949. https://pmc.ncbi.nlm.nih.gov/articles/PMC4864949/
8.Novel Molecular Aspects of Ghrelin and Leptin in the Control of Obesity and Metabolic Syndrome. (2014). Novel molecular aspects of ghrelin and leptin in the control of adipobiology and metabolic syndrome. Obesity Facts / PMC5644879. https://pmc.ncbi.nlm.nih.gov/articles/PMC5644879/
9.AMP-Activated Protein Kinase (AMPK): Master Regulator of Metabolic Syndrome. (2013). AMP-activated protein kinase (AMPK): Does this master regulator of cellular energy state distinguish metabolic syndrome? PMC4039173. https://pmc.ncbi.nlm.nih.gov/articles/PMC4039173/
10.Clinical Significance of Serum IL-6 and TNF-α Levels in Patients with Metabolic Syndrome. (2017). Clinical significance of serum IL-6 and TNF-α levels in patients with metabolic syndrome. PMC5643447. https://pmc.ncbi.nlm.nih.gov/articles/PMC5643447/
11.Association of Adipokines with Insulin Resistance and Metabolic Syndrome. (2025). Association of adipokines with insulin resistance and metabolic syndrome. Global Health & Medicine / PMC11933950. https://pmc.ncbi.nlm.nih.gov/articles/PMC11933950/
12.Adiponectin: Structure, Physiological Functions, and Role in Metabolic Syndrome. (2021). Adiponectin: Structure, physiological functions, role in diseases, and therapeutic potential. PMC8066826. https://pmc.ncbi.nlm.nih.gov/articles/PMC8066826/
Austria
Uzbekistan
United States
United Kingdom
Germany
France
Italy
Spain
Turkey
Saudi Arabia
United Arab Emirates
Qatar
Egypt
Jordan
India
Pakistan
Bangladesh
China
Japan
South Korea
Malaysia
Indonesia
Kazakhstan
Kyrgyzstan
Tajikistan